Loading stock data…
STVN
$18.10+0.10 (+0.56%)
After Hours$18.20+0.10 (+0.55%)· Last close Jun 9
Stevanato Group S.p.A.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stevanato Group S.p.A. in the Healthcare sector is trading at $18.10. Wall Street consensus targets $24.39 (9 analysts), implying a +34.7% move over the next 12 months. The stock is currently 35% below its 52-week high of $28.00, remaining 9.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +34.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$18.10
Potential Downside
0%
Whystock Fair Value$18.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$24.39+34.7%
Range$17.50 – $32.00
Fundamentals
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.23%
Volume
Today's trading volume
449,032
Recent News
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
Implied Volatility Surging for Stevanato Stock Options
Investors need to pay close attention to STVN stock based on the movements in the options market lately.
Earnings Beat: Stevanato Group S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Stevanato Group S.p.A. ( NYSE:STVN ) had a good week, as its shares rose 6.1% to close at US$18.03...
Stevanato (STVN) Q1 2026 Earnings Transcript
As we right-sized operations and streamlined processes, along with the better mix resulting from the delivery of legacy projects in Denmark, we are starting to harvest the benefits with initial profitability improvements in the segment. While the financial performance of the segment is not where we want it to be, the team is prioritizing execution, new business development, and returning the segment to its historical performance levels.
Stevanato Group S.p.A. Q1 2026 Earnings Call Summary
Moby summary of Stevanato Group S.p.A.'s Q1 2026 earnings call